(marketscreener.com) REMD Biotherapeutics, Inc. , together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd , today announced they have completed enrollment and have top-line results in a phase 2 study of volagidemab in patients with type 1 diabetes. The study, which enrolled approximately 150 patients at eleven clinical sites in the United States, is a...https://www.marketscreener.com/news/latest/REMD-Biotherapeutics-Completes-Enrollment-and-Announces-Top-line-Results-of-a-Phase-2-Clinical-Study--32141535/?utm_medium=RSS&utm_content=20210107
